专栏新型冠状病毒

Any Covid-19 vaccine must be treated as a global public good

Imagine if, in a year’s time, 300m doses of a safe and effective Covid-19 vaccine have been manufactured in Donald Trump’s America, Xi Jinping’s China or Boris Johnson’s Britain. Who is going to get them? What are the chances that a nurse in India, or a doctor in Brazil, let alone a bus driver in Nigeria or a diabetic in Tanzania, will be given priority? The answer must be virtually nil.

The ugly battle between nations over limited supplies of tests and personal protective equipment will be a sideshow compared to the scramble over a vaccine. Yet if a vaccine is to be anything like the silver bullet that some imagine, it will have to be available to the world’s poor as well as to its rich. 

Any vaccine should be deployed to create the maximum possible benefit to public health. That will mean prioritising doctors, nurses and other frontline workers, as well as those most vulnerable to the disease, no matter where they live or how much they can afford.

您已阅读20%(961字),剩余80%(3792字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。
版权声明:本文版权归manbetx20客户端下载 所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。

戴维•皮林

戴维•皮林(David Pilling)现为《金融时报》非洲事务主编。此前他是FT亚洲版主编。他的专栏涉及到商业、投资、政治和manbetx20客户端下载 方面的话题。皮林1990年加入FT。他曾经在伦敦、智利、阿根廷工作过。在成为亚洲版主编之前,他担任FT东京分社社长。

相关文章

相关话题

设置字号×
最小
较小
默认
较大
最大
分享×